Breakthrough findings demonstrate a possible target and potential drug treatment to restore memory loss and extend life span in mice with neurodegeneration
“We have treated mice with a new type of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression”
– Professor Andrew Tobin
An international team of scientists has announced a new advance in the fight against Alzheimer’s disease by identifying a new drug target for not only improving symptoms of brain degeneration – but also to extend the life-span of the terminally ill mice.
The four-year study by Medical Research Council (MRC) scientists based at the MRC Toxicology Unit at the University of Leicester is published in the Journal of Clinical Investigation. The study was led by Professor Andrew Tobin alongside colleagues from pharmaceutical company Eli Lilly and Company and the Monash Institute for Pharmaceutical Sciences in Australia. The project was also partly supported by the Wellcome Trust.
Corresponding author Professor Tobin, who alongside the lead researcher Dr Sophie Bradley has since moved from the University of Leicester to the University of Glasgow, said: “The paper describes drug-like molecules that can restore memory loss and slow progression of prion neurodegenerative disease in a manner that relates to the potential of these drugs in human Alzheimer’s disease.
“We have been using mice whose brain cells are progressively dying, similar to what happens in Alzheimer’s disease. This project focuses on a particular protein in the brain, which is proposed to be involved in Alzheimer’s disease, and as such could be a potential target for new drugs.
“We have treated mice with a new class of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice.”
The researchers state that drugs which activate this protein receptor in the brain have previously been tested in clinical trials for Alzheimer’s disease, and showed positive results with respect to improving cognition, but the patients experienced a large number of adverse side effects. This new class of drug is more selective and does not cause any side-effects when administered to mice in the study.
The study authors believe that this offers hope in the design of new drugs for improving cognition and extending life span.
Professor Tobin said: “This work may provide important information as to whether this protein is a viable drug target in the treatment of diseases associated with the progressive death of brain cells. This is of great importance to society, based on the fact that the treatment options for Alzheimer’s disease are very limited – there are no cures for Alzheimer’s disease and current treatments are focused on relieving some of the symptoms.
“What we have found is a novel class of drugs, called allosteric ligands, that target a protein called the M1 muscarinic receptor, which is present in the brain. Activating this receptor protein can not only improve cognitive function in mice with progressive brain degeneration, but when administered daily, can extend life span.”
The scientists say the work is important because it focuses on identifying a treatment that not only improves symptoms associated with neurodegeneration, like current treatments, but also identifies a new strategy for slowing disease progression and extending life-span.
Professor Tobin said: “Alzheimer’s disease is the most common form of dementia, and it affects an estimated 850,000 people in the UK alone. There are no treatments that can slow or halt the progression of Alzheimer’s, and patients are treated with drugs which temporarily mask the symptoms of the disease. Often these treatments are associated with side-effects which can limit patient compliance.
“I am proud to be involved in a collaboration with researchers across the world to address one of the world’s major healthcare challenges. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression.”
Receive an email update when we add a new ALZHEIMERS article.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- IG Wealth Management Walk for Alzheimer's Unites Canadians Virtually this Mayon May 3, 2021 at 9:19 am
Annual fundraiser brings help and hope to the escalating number of people impacted by dementiaTORONTO, May 3, 2021 /CNW/ - Canadians will come ...
- Low doses of radiation may improve quality of life for those with severe Alzheimer'son May 3, 2021 at 8:02 am
Individuals living with severe Alzheimer's disease showed remarkable improvements in behavior and cognition within days of receiving an innovative new treatment that delivered low doses of radiation, ...
- Alzheimer’s Shown to Develop in Four Distinct Patternson May 3, 2021 at 5:00 am
Scientists now have reason to reevaluate the concept of typical Alzheimer's and, in the long run, also the methods that are used to assess the progression of the disease.
- Tips for celebrating Mother's Day for women with Alzheimer'son May 3, 2021 at 4:00 am
In Montana alone, 22,000 people – more than 14,000 of them women – are living with Alzheimer’s disease, which is the last major disease without a prevention, treatment or cure.
- Alzheimer's Q&A: What does memory misattribution mean?on May 3, 2021 at 2:00 am
Misattribution occurs when you remember something correctly for the most part, but some detail, such as time or place or the person involved, isn't right.
- Genetic predisposition, Aβ misfolding in blood plasma, and Alzheimer’s diseaseon May 1, 2021 at 1:43 pm
Alzheimer’s disease is highly heritable and characterized by amyloid plaques and tau tangles in the brain. The aim of this study was to investigate the association between genetic predisposition, Aβ ...
- Memory Ball Going Virtual This Year To Raise Funds For Alzheimer’s Associationon May 1, 2021 at 5:35 am
In 2020, the Alzheimer's Association reported more than 110,000 Marylanders 65 and older were battling the disease.
- Missing 71-Year-Old Sacramento County Man With Alzheimer’s Found Safeon April 30, 2021 at 2:49 pm
The Sacramento County Sheriff’s Office says John Torgerson, who was reported missing on Wednesday, was found safe.
- Educating the public about dementia, Alzheimer'son April 30, 2021 at 12:52 pm
Susan Albers is tired of dancing around the issue, and Reilly Huelsmann said compassion training is needed. Albers, executive director of Bloom at Kokomo Senior Living, and Huelsmann, Alzheimer's ...
via Bing News